Phenylethylamine (PEA, beta-phenylethylamine, 2-phenylethylamine) is an endogenous trace amine neurotransmitter and the structural parent compound of the entire phenethylamine class — arguably the most pharmacologically significant chemical family in all of psychopharmacology. From PEA's simple two-carbon backbone, the addition of various substituents produces dopamine, norepinephrine, epinephrine, amphetamine, methamphetamine, MDMA, mescaline, and dozens of other psychoactive compounds. It is the chemical scaffolding upon which much of neuropharmacology is built. PEA is naturally produced in the human brain in small quantities, where it functions as a neuromodulator through the trace amine-associated receptor 1 (TAAR1), triggering the release of dopamine and norepinephrine from presynaptic terminals. PEA earned the nickname "the love molecule" after researchers discovered that brain PEA levels surge during romantic attraction — the racing heart, the euphoria, the obsessive focus on a new romantic interest are all partially mediated by PEA signaling. It is also present in chocolate, contributing to chocolate's enduring reputation as a mood elevator and romantic gift, though the amount of PEA in chocolate is too small to produce significant psychoactive effects after oral ingestion. PEA is also released during vigorous exercise, contributing to the "runner's high" alongside endorphins and endocannabinoids. As a supplement, PEA is sold for mood elevation, focus, and energy. However, its practical utility is severely limited by its extraordinarily rapid metabolism — monoamine oxidase B (MAO-B) destroys PEA within minutes of its synthesis or ingestion, giving it a half-life of approximately 5-10 minutes and an oral bioavailability of less than 5%. This metabolic vulnerability has led the nootropic community to develop stacking strategies with MAO-B inhibitors such as hordenine or selegiline to extend PEA's effects, a practice that carries its own significant risks.